X
<

Pfizer’s Post-2Q17 Update: Ibrance, Lyrica, and Biosimilars

PART:
1 2 3 4 5 6 7 8 9 10 11 12 13
Part 12
Pfizer’s Post-2Q17 Update: Ibrance, Lyrica, and Biosimilars PART 12 OF 13

An Update on Pfizer’s Legacy Established Products after 2Q17

Lipitor’s revenue trends

In 2Q17, Pfizer’s (PFE) Lipitor generated revenues of around $445 million, which is an ~3% decline on a year-over-year (or YoY) basis and 10% growth on a quarter-over-quarter basis. In 1H17, Lipitor generated revenues of ~$849 million compared to $872 million in 1H16. 

High demand in China was a primary contributor to the drug’s revenue growth in 2Q17, which was partially offset by lower sales volumes in Japan and some Middle Eastern markets. The chart below represents the revenue trajectory of Pfizer’s Legacy Established Products segment from 2Q16 to 2Q17.

An Update on Pfizer’s Legacy Established Products after 2Q17

Interested in PFE? Don't miss the next report.

Receive e-mail alerts for new research on PFE

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Norvasc’s revenue trends

In 2Q17, Norvasc reported revenues of around $231 million, which represents a 4% decline on a YoY basis and 1% growth on a quarter-over-quarter basis. In 1H17, Norvasc reported revenues of ~$458 million for 4% growth YoY. 

In 1H17, competition due to generic erosion in Japan and pricing pressures in China led to the decline in the drug’s YoY revenues, partially offset by high demand in China.

Premarin’s revenue trends

In 2Q17, Premarin posted revenues of ~$245 million which is a 2% decline YoY and 7% growth on a quarter-over-quarter basis. In 1H17, Premarin generated revenues of around $473 million, which reflected an ~7% decline on a YoY basis.

Relpax’s revenue trends

In 2Q17, Replax reported revenues of around $60 million for a 31% decline on a YoY basis and a 27% decline on a quarter-over-quarter basis. In 1H17, Replax generated revenues of around $143 million, which reflected an ~13% decline YoY.

EpiPen’s revenue trends

In 2Q17, EpiPen posted revenues of around $90 million, which represented a 3% decline YoY and 11% growth on a quarter-over-quarter basis. In 1H17, EpiPen generated revenues of ~$171 million, which reflected an ~10% decline on a YoY basis.

Zithromax’s revenue trends

In 2Q17, Zithromax reported revenues of ~$62 million, a 7% decline on a YoY basis and a 22% decline on a quarter-over-quarter basis. In 1H17, Zithromax generated revenues of ~$140 million compared to $147 million in 1H16.

Xalatan/Xalacom: Revenue trends

In 2Q17, Xalatan/Xalacom posted revenues of ~$81 million. which is a 14% decline YoY and 5% growth on a quarter-over-quarter basis. In 1H17, Xalatan/Xalacom generated revenues of ~$158 million for a 13% decline on a YoY basis.

Zoloft’s revenue trends

In 2Q17, Zoloft reported revenues of around $69 million, which is a 10% decline on a YoY basis and 1% growth on a quarter-over-quarter basis. In 1H17, Zoloft generated revenues of ~$137 million, which reflected an ~12% decline on a YoY basis.

Effexor’s revenue trends

In 2Q17, Effexor posted revenues of ~$73 million, which constitutes 9% growth on a YoY basis and 11% growth on a quarter-over-quarter basis. In 1H17, EpiPen generated revenues of ~$139 million compared to $137 million in 1H16.

Xanax’s revenue trends

In 2Q17, Xanax reported revenues of ~$52 million, which is a 5% decline on a YoY basis and a 5% decline on a quarter-over-quarter basis. In 1H17, EpiPen generated revenues of ~$107 million compared to $108 million in 1H16.

The Health Care Select Sector SPDR ETF (XLV) invests ~6.6% of its total portfolio holdings in Pfizer. XLV also invests ~11.8%, ~5.7%, and ~4.2% in Johnson & Johnson (JNJ), Merck (MRK), and Amgen (AMGN), respectively.

X

Please select a profession that best describes you: